Dextrose

Dextrose Monohydrate


Icu Medical Inc.
Human Prescription Drug
NDC 0990-7120
Dextrose also known as Dextrose Monohydrate is a human prescription drug labeled by 'Icu Medical Inc.'. National Drug Code (NDC) number for Dextrose is 0990-7120. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Dextrose drug includes Dextrose Monohydrate - 70 g/100mL . The currest status of Dextrose drug is Active.

Drug Information:

Drug NDC: 0990-7120
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dextrose
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Dextrose Monohydrate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Icu Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DEXTROSE MONOHYDRATE - 70 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jul, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019893
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:ICU Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:237656
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:LX22YL083G
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0990-7120-076 POUCH in 1 CASE (0990-7120-07) / 1 BAG in 1 POUCH / 2000 mL in 1 BAG01 Jul, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Dextrose dextrose monohydrate dextrose monohydrate anhydrous dextrose water

Indications and Usage:

Indications and usage 70% dextrose injection, usp (concentrated dextrose in water) in pharmacy bulk packages is indicated for use with automated compounding devices for preparing intravenous nutritional admixtures in the pharmacy.

Warnings:

Warnings concentrated dextrose in water should be administered only after suitable dilution. hypertonic dextrose solutions should be given slowly. significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. the physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance. the intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. warning : this product contains aluminum that may be toxic. aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminu
m. research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. tissue loading may occur at even lower rates of administration. for peripheral vein administration hypertonic dextrose solutions (above 5% concentration) should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation. for central venous administration concentrated dextrose should be administered via central vein after appropriate admixture or dilution when required.

Dosage and Administration:

Dosage and administration concentrated dextrose in water is administered by slow intravenous infusion (a) after admixture with amino acid solutions or (b) after dilution with other compatible iv fluids. dosage should be adjusted to meet the requirements of each individual patient. 70% dextrose injection, usp in the 2000 ml flexible pharmacy bulk package is designed for use with automated compounding devices for preparing intravenous nutritional admixtures. dosages will be in accordance with the recommendation of the prescribing physician. 70% dextrose injection, usp are not intended for direct infusion. admixtures should be made by, or under the direction of, a pharmacist using strict aseptic technique under a laminar flow hood. compounded admixtures may be stored under refrigeration for up to 24 hours. administration of admixtures should be completed within 24 hours after removal from refrigeration. the maximum rate at which dextrose can be infused without producing glycosuria is 0.5
g/kg of body weight/hr. about 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr. clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. as reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (see precautions .) drug interactions additives may be incompatible with the fluid withdrawn from this container. consult with pharmacist, if available. when compounding admixtures, use aseptic technique, mix thoroughly and do not store. some opacity of the plastic due to moisture absorption during sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. recommended directions for use of the pharmacy bulk package use aseptic technique 1. during use, container must be stored, and all manipulations performed, in an appropriate laminar flow hood. 2. remove cover from outlet port at bottom of container. 3. insert piercing pin of transfer set and suspend unit in a laminar flow hood. insertion of a piercing pin into the outlet port should be performed only once in a pharmacy bulk package solution. once the outlet site has been entered, the withdrawal of container contents should be completed promptly in one continuous operation. should this not be possible, a maximum time of 4 hours from transfer set pin or implement insertion is permitted to complete fluid transfer operations; i.e., discard container no later than 4 hours after initial closure puncture. 4. sequentially dispense aliquots of 70% dextrose injection, usp into iv containers using appropriate transfer set. during fluid transfer operations, the pharmacy bulk package should be maintained under the storage conditions recommended in the labeling.

Contraindications:

Contraindications a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present nor in the presence of delirium tremens if the patient is already dehydrated. dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

Adverse Reactions:

Adverse reactions hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause hypovolemia, dehydration, mental confusion and/or loss of consciousness. reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Overdosage:

Overdosage in the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures. (see warnings and precautions ).

Description:

Description 70% dextrose injection, usp (concentrated dextrose in water) is a sterile, nonpyrogenic, hypertonic solution of dextrose, usp in water for injection for intravenous administration after appropriate admixture or dilution. the pharmacy bulk package is a sterile dosage form which contains multiple single doses for use only in a pharmacy bulk admixture program. the content and physical characteristics of the solutions are as follows: solution characteristics 70% dextrose injection, usp ph 4.0 ph range 3.2 - 6.5 osmolarity (mosmol/l) (calc.) 3532 specific gravity 1.236 grams dextrose/100 ml 70 kcal/100 ml caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous. 238 fill volume (ml) 2000 the solutions contain no bacteriostat, antimicrobial agent or added buffer and are intended only for use as a single-dose injection following admixture or dilution. this pharmacy bulk package is intended only for use in the preparation of sterile, intravenous nutrient admixtures using automated compounding devices. the flexible plastic container is fabricated from a specially formulated polyvinylchloride. water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. exposure to temperatures above 25°c/77°f during transport and storage will lead to minor losses in moisture content. higher temperatures lead to greater losses. it is unlikely that these minor losses will lead to clinically significant changes within the expiration period. dextrose injection, usp is a parenteral fluid and nutrient replenisher. dextrose, usp is chemically designated d-glucose, monohydrate (c 6 h 12 o 6 • h 2 o), a hexose sugar freely soluble in water. it has the following structural formula: water for injection, usp is chemically designated h 2 o. dextrose structural formula

Clinical Pharmacology:

Clinical pharmacology when administered intravenously, solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein sparing action. dextrose injection undergoes oxidation to carbon dioxide and water. water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). water balance is maintained by various regulatory mechanisms. water distribution depends primarily on the concentration of electrolytes in the body compartments, and sodium (na + ) plays a major role in maintaining physiologic equilibrium.

How Supplied:

How supplied 70% dextrose injection, usp are supplied as follows: ndc no. container concentration fill 0409-7120-07 flexible pharmacy bulk package 70% 2000 ml 0990-7120-07 icu medical is transitioning ndc codes from the "0409" to a "0990" labeler code. both ndc codes are expected to be in the market for a period of time. store at 20 to 25°c (68 to 77°f). [see usp controlled room temperature.] protect from freezing. revised: june 2018 en-4656 icu medical, inc., lake forest, illinois, 60045, usa

Package Label Principal Display Panel:

Principal display panel - 70 g bag label 2000 ml ndc 0990-7120-07 dextrose injection, usp 70% pharmacy bulk package — not for direct infusion. must be diluted. each 100 ml contains dextrose, hydrous, usp 70 g in water for injection. hypertonic osmolarity 3532 mosmol/liter (calc). ph 4.0 (3.2 to 6.5) specific gravity 1.236 sterile, nonpyrogenic. dosage and administration: see package insert. caution: do not use unless solution is clear, closure is intact, and container is undamaged. check for minute leaks by squeezing firmly. if leaks are found discard container and contents as sterility may be impaired. within 4 hours after initial entry discard container and unused contents. date entered: time of entry: store at 20 to 25°c (68 to 77°f). [see usp controlled room temperature.] protect from freezing. this product contains no more than 25 mcg/l of aluminum. rx only 70% 3 v contains dehp im-4368 icu medical, inc., lake forest, illinois, 60045, usa icumedical principal display panel - 70 g bag label

Principal display panel - 70 g bag overwrap label to open — tear at notch the overwrap is a moisture and oxygen barrier. do not remove unit from overwrap until ready for use. visually inspect overwrap for tears or holes. use unit promptly when pouch is opened. store at 20 to 25°c (68 to 77°f). [see usp controlled room temperature.] protect from freezing. see insert. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. color variation in the dextrose injection from pale yellow to yellow is normal and does not alter efficacy. rx only wr-0523 icu medical, inc., lake forest, illinois, 60045, usa icumedical principal display panel - 70 g bag overwrap label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.